BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement